DA Davidson downgraded shares of Imperva Inc. (NYSE:IMPV) from a buy rating to a neutral rating in a research note published on Thursday. DA Davidson currently has $55.00 price target on the stock. The analysts noted that the move was a valuation call.

A number of other equities research analysts also recently commented on IMPV. Oppenheimer Holdings Inc. reissued a buy rating and issued a $60.00 price objective on shares of Imperva in a research report on Tuesday, June 21st. Nomura reissued a buy rating and issued a $60.00 price objective on shares of Imperva in a research report on Tuesday, June 21st. BTIG Research reissued a buy rating and issued a $55.00 price objective on shares of Imperva in a research report on Tuesday, June 21st. Needham & Company LLC reissued a hold rating on shares of Imperva in a research report on Tuesday, June 21st. Finally, Morgan Stanley reissued a sell rating on shares of Imperva in a research report on Thursday, June 30th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. Imperva has a consensus rating of Hold and a consensus target price of $52.33.

Analyst Recommendations for Imperva (NYSE:IMPV)

Shares of Imperva (NYSE:IMPV) traded down 2.99% during trading on Thursday, reaching $51.66. 599,907 shares of the company traded hands. The firm’s 50 day moving average price is $47.72 and its 200-day moving average price is $44.68. Imperva has a 52 week low of $31.11 and a 52 week high of $77.99. The company’s market capitalization is $1.68 billion.

Imperva (NYSE:IMPV) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.19. Imperva had a negative net margin of 23.75% and a negative return on equity of 25.68%. The firm earned $57.87 million during the quarter, compared to analysts’ expectations of $66.06 million. During the same period in the prior year, the company posted ($0.08) earnings per share. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. Equities analysts anticipate that Imperva will post ($0.80) EPS for the current fiscal year.

In related news, SVP Mark E. Kraynak sold 5,582 shares of the company’s stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $51.00, for a total value of $284,682.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Amichai Shulman sold 938 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $53.27, for a total transaction of $49,967.26. Following the completion of the sale, the insider now directly owns 95,085 shares in the company, valued at $5,065,177.95. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its stake in Imperva by 2,252.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,352 shares of the company’s stock valued at $101,000 after buying an additional 2,252 shares in the last quarter. Bank of Montreal Can bought a new stake in Imperva during the second quarter valued at about $107,000. BlackRock Inc. boosted its stake in Imperva by 37.1% in the second quarter. BlackRock Inc. now owns 2,596 shares of the company’s stock valued at $111,000 after buying an additional 703 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Imperva by 63.6% in the third quarter. BNP Paribas Arbitrage SA now owns 3,169 shares of the company’s stock valued at $170,000 after buying an additional 1,232 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA bought a new stake in Imperva during the second quarter valued at about $147,000. 93.26% of the stock is currently owned by hedge funds and other institutional investors.

Imperva Company Profile

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.

5 Day Chart for NYSE:IMPV

Receive News & Stock Ratings for Imperva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc. and related stocks with our FREE daily email newsletter.